纳入标准:2018年12月至2023年1月期间35例菲莫西妥增强MRI申请,经放射科医师二次评估后纳入24例(中位年龄58岁,范围13-81岁),涵盖eGFR<60 mL/min/1.73m²患者(含12例透析依赖者)。 给药方案 剂量与输注:4 mg/kg静脉注射(稀释至30 mL生理盐水),速率1 mL/s,全程监测生命体征及过敏反应。 评估体系 定性...
Nguyen K-L, Yoshida T, Kathuria-Prakash N, et al.Multicenter safety and practice for off-label diagnostic use of ferumoxytol in MRI. Radiology 2019; 293:554-564. Schieda N.Parenteral ferumoxytol interaction with magnetic resonance imaging: a case report, review of the literature and advisory ...
Each patient was either intubated in the neonatal intensive care unit (NICU) or underwent general anesthesia at MRI suite. For 2D analysis, we reformatted MUSIC images in Digital Imaging and Communications in Medicine (DI...
Objectives Ultra-small superparamagnetic particles of iron oxide (USPIO)-enhanced MRI can detect cellular inflammation within tissues and may help non-invasively identify cardiac transplant rejection. Here, we aimed to determine the normal reference values for USPIO-enhanced MRI in patients with a prior...
2.磁性能:ferumoxytol聚葡萄糖山梨醇羧甲基醚具有优异的磁性能,可以用于磁共振成像(MRI)和磁导航等医学应用领域。这种纳米粒子药物具有高磁饱和度和磁导率,能够提高MRI的灵敏度和分辨率。 3.药物释放动力学:ferumoxytol聚葡萄糖山梨醇羧甲基醚作为一种缓释纳米载体,其药物释放速率可以通过调节聚合物的渗透性和纳米粒子的...
Ferumoxytol(Feraheme, AMAG Pharmaceuticals, Waltham, MA, USA) is a therapeutic agent used in the treatment of iron-deficientanaemiathat has also been applied as a non-gadolinium magnetic resonance imaging (MRI)contrast agentwith uses throughout the body. Its unique properties allow it to assess ...
Ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA, USA) is a therapeutic agent used in the treatment of iron-deficient anaemia that has also been applied as a non-gadolinium magnetic resonance imaging (MRI) contrast agent with uses throughout the body. Its unique properties allow it to ...
OBJECTIVE: To investigate the safety, tolerability, and neuroimaging characteristics of ferumoxytol-enhanced brain MRI in HAND.BACKGROUND: Monocytes/Macrophages (M/M桅) have a key role in the pathogenesis of HIV-Associated Neurocognitive Disorders (HAND). Ferumoxytol is a MRI contrast agent avidly tak...
This study describes our initial institutional experience of ferumoxytol-enhanced MRI (feMRI) for differentiating intrapancreatic splenules (IPS) from other pancreatic lesions. Methods In this retrospective study, patients with computed tomographic imaging that identified small enhancing lesions in the tail...
In addition, this agent generates T1 relaxation, producing a magnetic field and enhancing T2 relaxation, thereby darkening contrast media-containing structures in magnetic resonance imaging (MRI). Due to small particle size, ferumoxytol remains in the intravascular space for a prolonged period and so ...